FDA approves brain stimulation device for Parkinson's disease

June 14, 2015
FDA approves brain stimulation device for parkinson's disease
Brio Neurostimulation System is second such device approved for tremor disorders.

(HealthDay)—The U.S. Food and Drug Administration on Friday approved a device that can be implanted into the brain to help people battling Parkinson's disease.

The Brio Neurostimulation System is "an implantable to help reduce the symptoms of Parkinson's disease and essential tremor, a movement disorder that is one of the most common causes of tremors," the FDA said in a news release.

The agency estimates that about 50,000 Americans are diagnosed with Parkinson's annually, while essential tremor affects "several million" people, most over the age of 40.

"There are no cures for Parkinson's disease or essential tremor, but finding better ways to manage symptoms is essential for patients," Dr. William Maisel, acting director of the Office of Device Evaluation at the FDA's Center for Devices and Radiological Health, said in the news release.

"This new device adds to the array of treatment options to help people living with Parkinson's and essential tremor enjoy better, more productive lives," he said.

The device is consists of a small, rechargeable battery-powered "pulse generator" implanted under the skin. Wire leads from the generator lead to specific brain locations, depending on the illness under treatment. People trained in using the devices can adjust the pulse generator's effects as needed, the FDA said.

The Brio Neurostimulation System was approved based on the results of two clinical trials, one involving 136 patients with Parkinson's disease who used the device for three months, and another involving 127 patients with essential tremor who used it for six months. In both studies, medications had already failed to control patients' symptoms, the FDA said.

"Both groups showed statistically significant improvement on their primary effectiveness endpoint when the device was turned on, compared to when it was turned off," the agency said.

The device does not come without risk, including intracranial bleeding which can lead to stroke, paralysis or death, the FDA said. Infection and device dislocation are also potential risks.

"Brio Neurostimulation System is the second device approved by the FDA for Parkinson's and essential tremor," the agency said. "The first device, Medtronic's Activa Deep Brain Stimulation Therapy System, was approved in 1997 for tremor associated with and Parkinson's disease. In 2002, the indications were expanded to include the symptoms of Parkinson's disease."

Explore further: Focused ultrasound for treating Parkinson's disease to be tested

More information: There's more on Parkinson's disease at the National Parkinson's Foundation.

Related Stories

Focused ultrasound for treating Parkinson's disease to be tested

October 12, 2012
(Medical Xpress)—After a promising clinical trial of focused ultrasound as a potential treatment for essential tremor, the University of Virginia Health System is launching a new study to investigate the scalpel-free technology's ...

Demand-driven deep brain stimulation to treat Parkinson's disease

April 15, 2015
Researchers from the Centre for Biomedical Technology (CTB) at Universidad Politécnica de Madrid (UPM) have participated in a joint research project with Universidad Carlos III de Madrid and University of Reading (United ...

Medtronic device will collect data as it treats brain disorders

August 13, 2013
A new deep brain stimulation system by Medtronic can sense and record brain activity at the same time it delivers therapy to treat Parkinson's symptoms, essential tremors and epilepsy. The data collected by the Activa PC+S ...

DBS operation for Parkinson's disease performed inside iMRI

September 19, 2011
Henry Ford Hospital became the third hospital in the United States to perform a Deep Brain Stimulation (DBS) procedure inside an Intraoperative Magnetic Resonance Imaging scanner, or iMRI.

Spinal stimulation system relieves pain without tingling

May 11, 2015
(HealthDay)—The Senza spinal cord stimulation system has been approved by the U.S. Food and Drug Administration to treat chronic back pain without the tingling sensation that characterizes more traditional pain-relieving ...

Recommended for you

Genetic defects in the cell's 'waste disposal system' linked to Parkinson's disease

November 14, 2017
An international study has shed new light on the genetic factors associated with Parkinson's disease, pointing at a group of lysosomal storage disorder genes as potential major contributors to the onset and progression of ...

Parkinson's disease: A looming pandemic

November 13, 2017
New research shows that the number of people with Parkinson's disease will soon grow to pandemic proportions. In a commentary appearing today in the journal JAMA Neurology, University of Rochester Medical Center neurologist ...

Focused ultrasound shows promise for treating Parkinson's tremor

October 30, 2017
An initial test to determine if a scalpel-free form of brain surgery can reduce tremor caused by Parkinson's disease has produced encouraging results. Further research is warranted, the researchers conclude in a paper published ...

Novel technique explains herbicide's link to Parkinson's disease

October 23, 2017
Northwestern Medicine scientists have used an innovative gene editing technique to identify the genes that may lead to Parkinson's disease after exposure to paraquat, a commonly-used herbicide.

Data, technology drive new approaches to Parkinson's care

October 23, 2017
Complex, multi-system diseases like Parkinson's have long posed challenges to both scientists and physicians. University of Rochester Medical Center (URMC) researchers are now reaching for new tools, such as algorithms, ...

Investigating the most common genetic contributor to Parkinson's disease

October 19, 2017
LRRK2 gene mutations are the most common genetic cause of Parkinson's disease (PD), but the normal physiological role of this gene in the brain remains unclear. In a paper published in Neuron, Brigham and Women's Hospital ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.